Market Cap 164.34M
Revenue (ttm) 1.55M
Net Income (ttm) -63.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,068.39%
Debt to Equity Ratio 0.00
Volume 1,047,600
Avg Vol 1,383,128
Day's Range N/A - N/A
Shares Out 124.50M
Stochastic %K 69%
Beta 0.97
Analysts Strong Sell
Price Target $6.33

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 336 0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
trendsetter20
trendsetter20 Jul. 4 at 1:02 PM
$MIST Two short interest numbers are quoted as a percentage of the float. One is 41% and the other is 9%. The difference is that some institutional holders like RTW are restricted from selling their stock. Regardless of the monthly or quarterly script numbers, the sales will rise quarter over quarter until they reach critical mass. It doesn't really matter if they miss a quarter because the patient demand will grow and that is most important. The question is: at what level did the shorts apply their short and how do they escape. Right now, I suspect they are hoping for good script number that will drive the stock to 1.50 before June 15th. What that tells you is that even a dumb person can make 10% in the next 7 trading days. If the stock does not get to $1.50 in the next 7 trading days, the shorts are really screwed. It is going to be a fascinating 7 days ...
2 · Reply
alexpitti
alexpitti Jul. 3 at 5:30 PM
new york city public library has free bloomberg terminals. if i want to see scripts from june, what day should i go? next week? $MIST
5 · Reply
CCC501
CCC501 Jul. 3 at 4:23 PM
$MIST https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-reports-inducement-grants-under-8
1 · Reply
alexpitti
alexpitti Jul. 2 at 10:22 PM
happy 4th of july $STXS $DCTH $ABEO $ADBE $MIST
2 · Reply
Diverstj981
Diverstj981 Jul. 2 at 6:45 PM
$MIST Added 10k @ $1.31. 262k total. Warrants expiring soon, commercialization scaling, 2 major PBM's / EU and China / Medicare all pending and eventually AFib? Patience here will pay and pay handsomely.
4 · Reply
Biocontrol
Biocontrol Jul. 2 at 5:55 PM
$MIST series A warrants expire in 10 days - 1.50 exercise. Think they’ll run it up to exercise?
2 · Reply
alexpitti
alexpitti Jul. 2 at 5:50 PM
$MIST stop focusing on day to day. We have 3-4 more months of waiting. Can you do it?
1 · Reply
soccerfan913
soccerfan913 Jul. 2 at 5:29 PM
$MIST Merry Christmas!
0 · Reply
alexpitti
alexpitti Jul. 2 at 3:30 PM
$MIST stop complaining and hold until October
2 · Reply
richb477
richb477 Jul. 2 at 2:50 PM
$MIST 1.35 all day till close at 1.28 Same pattern everyday
0 · Reply
Latest News on MIST
Milestone Pharmaceuticals Slides: Corporate presentation

Jun 1, 2026, 7:00 AM EDT - 4 weeks ago

Milestone Pharmaceuticals Slides: Corporate presentation


Milestone Pharmaceuticals files $300M mixed securities shelf

2026-05-13T21:54:39.000Z - 7 weeks ago

Milestone Pharmaceuticals files $300M mixed securities shelf


Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c

2026-05-13T12:41:15.000Z - 7 weeks ago

Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c


Milestone Pharmaceuticals Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Earnings Call Transcript: Q1 2026


Milestone Pharmaceuticals Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Quarterly report: Q1 2026


Milestone Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Earnings release: Q1 2026


Milestone Pharmaceuticals Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Slides: Corporate presentation


Milestone Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Milestone Pharmaceuticals Proxy statement: Proxy filing


Milestone Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Milestone Pharmaceuticals Proxy statement: Proxy filing


Milestone Pharmaceuticals Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Milestone Pharmaceuticals Slides: Corporate presentation


Milestone Pharmaceuticals provides details on RESET-PSVT trial

2026-04-10T12:06:08.000Z - 3 months ago

Milestone Pharmaceuticals provides details on RESET-PSVT trial


Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 20, 2026, 8:30 AM EDT - 3 months ago

Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025


Milestone Pharmaceuticals Earnings release: Q4 2025

Mar 20, 2026, 8:30 AM EDT - 3 months ago

Milestone Pharmaceuticals Earnings release: Q4 2025


Milestone Pharmaceuticals Annual report: Q4 2025

Mar 20, 2026, 8:30 AM EDT - 3 months ago

Milestone Pharmaceuticals Annual report: Q4 2025


Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c)

2026-03-20T11:21:41.000Z - 3 months ago

Milestone Pharmaceuticals reports Q4 EPS (16c), consensus (18c)


Milestone Pharmaceuticals to present Cardamyst data at ACC 26

2026-03-16T12:23:37.000Z - 3 months ago

Milestone Pharmaceuticals to present Cardamyst data at ACC 26


Milestone Pharmaceuticals Slides: Corporate presentation

Feb 6, 2026, 7:00 AM EST - 5 months ago

Milestone Pharmaceuticals Slides: Corporate presentation


Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen

2025-12-15T15:05:16.000Z - 7 months ago

Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen


Milestone Pharmaceuticals Transcript: FDA Announcement

Dec 15, 2025, 8:00 AM EST - 7 months ago

Milestone Pharmaceuticals Transcript: FDA Announcement


Milestone Pharmaceuticals Press release: FDA Announcement

Dec 15, 2025, 8:00 AM EST - 7 months ago

Milestone Pharmaceuticals Press release: FDA Announcement


Milestone Pharmaceuticals Slides: FDA Announcement

Dec 15, 2025, 8:00 AM EST - 7 months ago

Milestone Pharmaceuticals Slides: FDA Announcement


Milestone Pharmaceuticals receives FDA approval of CARDAMYST

2025-12-14T16:30:25.000Z - 7 months ago

Milestone Pharmaceuticals receives FDA approval of CARDAMYST


Milestone Pharmaceuticals Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Milestone Pharmaceuticals Earnings release: Q3 2025


Milestone Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 8 months ago

Milestone Pharmaceuticals Quarterly report: Q3 2025


Milestone Pharmaceuticals Slides: Company Presentation

Nov 12, 2025, 7:00 AM EST - 8 months ago

Milestone Pharmaceuticals Slides: Company Presentation


Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 19, 2025, 8:00 AM EDT - 11 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences


Milestone Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Milestone Pharmaceuticals Earnings release: Q2 2025


Milestone Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Milestone Pharmaceuticals Quarterly report: Q2 2025


Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Proposed Public Offering


Milestone Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Earnings release: Q1 2025


Milestone Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Quarterly report: Q1 2025


Milestone Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Proxy statement: Proxy Filing


Milestone Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Proxy statement: Proxy Filing


FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 1 year ago

FDA Issues Complete Response Letter for Etripamil for PSVT


Milestone Pharmaceuticals Annual report: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Annual report: Q4 2024


Milestone Pharmaceuticals Earnings release: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Earnings release: Q4 2024


Milestone Pharmaceuticals Transcript: Investor update

Feb 25, 2025, 10:30 AM EST - 1 year ago

Milestone Pharmaceuticals Transcript: Investor update


Milestone Pharmaceuticals Slides: Investor update

Feb 25, 2025, 10:30 AM EST - 1 year ago

Milestone Pharmaceuticals Slides: Investor update


Milestone Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals Earnings release: Q3 2024


Milestone Pharmaceuticals Slides: Corporate Presentation

Nov 12, 2024, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals Slides: Corporate Presentation


Milestone Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Earnings release: Q2 2024


Milestone Pharmaceuticals Proxy statement: Proxy Filing

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Proxy statement: Proxy Filing


Milestone Pharmaceuticals Proxy statement: Proxy Filing

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Proxy statement: Proxy Filing


Milestone Pharmaceuticals Proxy statement: Proxy Filing

Jul 15, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Proxy statement: Proxy Filing


Milestone Pharmaceuticals Transcript: Study update

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Transcript: Study update


Milestone Pharmaceuticals Earnings release: Q1 2024

May 13, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Earnings release: Q1 2024


Milestone Pharmaceuticals Annual report: Q4 2023

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Annual report: Q4 2023


Milestone Pharmaceuticals Earnings release: Q4 2023

Mar 21, 2024, 9:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Earnings release: Q4 2023


trendsetter20
trendsetter20 Jul. 4 at 1:02 PM
$MIST Two short interest numbers are quoted as a percentage of the float. One is 41% and the other is 9%. The difference is that some institutional holders like RTW are restricted from selling their stock. Regardless of the monthly or quarterly script numbers, the sales will rise quarter over quarter until they reach critical mass. It doesn't really matter if they miss a quarter because the patient demand will grow and that is most important. The question is: at what level did the shorts apply their short and how do they escape. Right now, I suspect they are hoping for good script number that will drive the stock to 1.50 before June 15th. What that tells you is that even a dumb person can make 10% in the next 7 trading days. If the stock does not get to $1.50 in the next 7 trading days, the shorts are really screwed. It is going to be a fascinating 7 days ...
2 · Reply
alexpitti
alexpitti Jul. 3 at 5:30 PM
new york city public library has free bloomberg terminals. if i want to see scripts from june, what day should i go? next week? $MIST
5 · Reply
CCC501
CCC501 Jul. 3 at 4:23 PM
$MIST https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-reports-inducement-grants-under-8
1 · Reply
alexpitti
alexpitti Jul. 2 at 10:22 PM
happy 4th of july $STXS $DCTH $ABEO $ADBE $MIST
2 · Reply
Diverstj981
Diverstj981 Jul. 2 at 6:45 PM
$MIST Added 10k @ $1.31. 262k total. Warrants expiring soon, commercialization scaling, 2 major PBM's / EU and China / Medicare all pending and eventually AFib? Patience here will pay and pay handsomely.
4 · Reply
Biocontrol
Biocontrol Jul. 2 at 5:55 PM
$MIST series A warrants expire in 10 days - 1.50 exercise. Think they’ll run it up to exercise?
2 · Reply
alexpitti
alexpitti Jul. 2 at 5:50 PM
$MIST stop focusing on day to day. We have 3-4 more months of waiting. Can you do it?
1 · Reply
soccerfan913
soccerfan913 Jul. 2 at 5:29 PM
$MIST Merry Christmas!
0 · Reply
alexpitti
alexpitti Jul. 2 at 3:30 PM
$MIST stop complaining and hold until October
2 · Reply
richb477
richb477 Jul. 2 at 2:50 PM
$MIST 1.35 all day till close at 1.28 Same pattern everyday
0 · Reply
alexpitti
alexpitti Jul. 1 at 6:01 PM
$MIST $MIST catalysts August call Q3 china approval 2h PBM deals with cvs and optumRX October inclusion on Medicare part d formulary q2 2027 eu approval 2028 data on afib trial
2 · Reply
TheYoungGeologist
TheYoungGeologist Jul. 1 at 4:37 PM
$MIST here's to a great Q3 everyone 🥂
0 · Reply
PortfolioMgmt23
PortfolioMgmt23 Jul. 1 at 4:20 PM
$MIST Wake me in Q3 when we have Part D coverage. Until then, we just let the sales and contracting teams cook. Series A Warrants are about to expire in 13 days. Cash position is strong. Steady as she goes.
1 · Reply
skismenos
skismenos Jul. 1 at 3:23 PM
Mist
3 · Reply
alexpitti
alexpitti Jul. 1 at 2:32 PM
$MIST is in a nice situation here because if the stock rises a bit and they do get exercised, they get cash. if not, no dillution the only bad thing would be if the stock was at like $3 and then exercised because that's dillution at a lower value. if the stock rises to $1.55 in the next 2 weeks (unlikely) it's like just tapping the atm
2 · Reply
JuggernautRaider
JuggernautRaider Jul. 1 at 7:53 AM
$MIST another savvy move by Milestone 🪨 yet $TNXP has no major partnerships with fibromyalgia patient advocacy groups 😡 FIRE SETH AS CEO!!! 🗳️
1 · Reply
JuggernautRaider
JuggernautRaider Jul. 1 at 7:50 AM
$MIST i love penny stocks like MIST… 💊 whether it goes up or down, the investment banks, other investors, and I are making money off of Milestone as its launch struggles. 🚀 Why aren’t you? 🤨 Ride the wave 🌊
1 · Reply
KilroyPicks
KilroyPicks Jun. 30 at 10:11 PM
$MIST - looking at todays chart looks like a large 500,000 share block traded at the close at the ask price.
2 · Reply
KilroyPicks
KilroyPicks Jun. 30 at 10:00 PM
$MIST - I have posted this before, these are my projections based on the q1 reports and extrapolating to Q2. I would reasonably expect revenue between $700,000 to $1.1 million for Q2. Q3 I would expect a revenue range between $2.2 Million and $3.2 Million and Q4 between $4 Million and $5.5 Million. Full year revenue between $7.13 Million and $10 Million on the high side. Hopefully the scripts accelerate faster than I predict. Based on my expectations the scripts volume needed are as follows. Q2 - 1,400 to 2,200 Q3 - 4,400 to 6,400 Q4 - 8,000 to 11,000
1 · Reply
Vincybull
Vincybull Jun. 30 at 8:30 PM
$MIST Do you have any idea what the revenue for Q2 2026 will be? Will it reach 4 million?
3 · Reply
KilroyPicks
KilroyPicks Jun. 30 at 7:46 PM
$MIST - The critical regulatory details and expected timeline for its launch in China include: Expected NMPA Approval: The NMPA is anticipated to issue a final approval decision for CARDAMYST in the third quarter of 2026. Commercialization Rights: The drug was originally advanced in China through a partnership with Corxel Pharmaceuticals (formerly Ji Xing Pharmaceuticals). However, in March 2026, Everest Medicines acquired the exclusive rights to develop and commercialize CARDAMYST across Greater China (including mainland China, Hong Kong, Macao, and Taiwan). Clinical Trial Foundations: The application is heavily backed by successful data from the Chinese Phase 3 trial (JX02002), which met its primary efficacy endpoint by significantly accelerating the conversion of abnormal rapid heartbeats to a normal sinus rhythm within 30 minutes, mirroring the drug's global Phase 3 RAPID trial results.
0 · Reply
alexpitti
alexpitti Jun. 30 at 5:41 PM
the $MIST short interest increased to a new high of 10.6 million. it's still below 9% which isn't that unusual
0 · Reply